Metastatic prostate cancer remains a leading cause of cancer mortality, with more than 30,000 deaths annually in the U.S. despite multiple prior lines of therapy. PSMA-SIR-T™, a first-in-class engineered autologous T-cell therapy, has demonstrated in preclinical studies durable tumor control, specificity to PSMA, and a modest cytokine release profile: a favorable safety signal absent in current cell therapy approaches. Its purpose-built SIR-T™ design is completely new, engineered to overcome the core failures of cell therapy. To learn more about SIR-T™ click here to watch a webinar from Dr. Preet M. Chaudhary, MD PhD, Professor of Medicine and Chief of Jane Ann Nohl Division of Hematology and Center for the Study of Blood Diseases at University of Southern California (USC) Keck School of Medicine, Director of USC Blood and Marrow Transplant and Cell Therapy Program.
